Literature DB >> 1360812

Smoking and schizophrenia.

J B Lohr1, K Flynn.   

Abstract

Several studies have shown that patients with schizophrenia have an extremely high prevalence of smoking, almost 90%, compared to only 33% in the general population and 45-70% in patients with other psychiatric diagnoses. The reasons for the high prevalence of smoking among schizophrenics is unknown, but it is likely that smoking behavior in schizophrenia may be a complex process, related to numerous interrelationships between the psychopathological, biochemical, and neuropharmacological aspects of smoking and of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1360812     DOI: 10.1016/0920-9964(92)90024-y

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  50 in total

1.  Genetic interaction between alpha4 and beta2 subunits of high affinity nicotinic receptor: analysis in schizophrenia.

Authors:  Vincenzo De Luca; Sophocles Voineskos; Greg Wong; James L Kennedy
Journal:  Exp Brain Res       Date:  2006-04-25       Impact factor: 1.972

Review 2.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 3.  Nicotinic modulation of neuronal networks: from receptors to cognition.

Authors:  Huibert D Mansvelder; Karlijn I van Aerde; Jonathan J Couey; Arjen B Brussaard
Journal:  Psychopharmacology (Berl)       Date:  2005-07-02       Impact factor: 4.530

4.  Quality of life and social functioning of former long-stay psychiatric patients transferred into the community: a 10 year follow up study.

Authors:  S J McInerney; S Finnerty; E Walsh; L Spelman; N E Edgar; B Hallahan; C McDonald
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2018-04-28       Impact factor: 4.328

5.  Homeostatic imbalance of purine catabolism in first-episode neuroleptic-naïve patients with schizophrenia.

Authors:  Jeffrey K Yao; George G Dougherty; Ravinder D Reddy; Matcheri S Keshavan; Debra M Montrose; Wayne R Matson; Joseph McEvoy; Rima Kaddurah-Daouk
Journal:  PLoS One       Date:  2010-03-03       Impact factor: 3.240

6.  Cholinergic systems are essential for late-stage maturation and refinement of motor cortical circuits.

Authors:  Dhakshin S Ramanathan; James M Conner; Arjun A Anilkumar; Mark H Tuszynski
Journal:  J Neurophysiol       Date:  2014-12-10       Impact factor: 2.714

7.  Effects of intravenous nicotine on prepulse inhibition in smokers and non-smokers: relationship with familial smoking.

Authors:  David J Drobes; David A MacQueen; Melissa D Blank; Michael E Saladin; Robert J Malcolm
Journal:  Psychopharmacology (Berl)       Date:  2013-04-28       Impact factor: 4.530

8.  A Reasonable Alternative to Clozapine in the Chronically Relapsing Smoking Patient? A Retrospective Analysis.

Authors:  John R Tomko; Nadeem Ahmed; Cynthia Kuntz; Justine Zick
Journal:  Hosp Pharm       Date:  2016-11

9.  Cigarettes and suicide: a prospective study of 50,000 men.

Authors:  M Miller; D Hemenway; E Rimm
Journal:  Am J Public Health       Date:  2000-05       Impact factor: 9.308

10.  MBD-seq as a cost-effective approach for methylome-wide association studies: demonstration in 1500 case--control samples.

Authors:  Karolina A Aberg; Joseph L McClay; Srilaxmi Nerella; Lin Y Xie; Shaunna L Clark; Alexandra D Hudson; Jozsef Bukszár; Daniel Adkins; Christina M Hultman; Patrick F Sullivan; Patrik K E Magnusson; Edwin J C G van den Oord
Journal:  Epigenomics       Date:  2012-12       Impact factor: 4.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.